Document Detail


Itraconazole oral solution for the treatment of tinea capitis.
MedLine Citation:
PMID:  9764158     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-seven children (12 boys, 15 girls, age range 3-11 years, weight range 10-40 kg) were treated with itraconazole oral solution 10 mg/mL given as pulse therapy for tinea capitis. The dosage regimen was 3 mg/kg per day given once daily in a fasting state with each pulse lasting 1 week. The first two pulses were separated by a 2-week off-drug period, and the second and third pulses had a 3-week period without drug between them. For each patient a second and third pulse were administered if there was clinical evidence of tinea capitis at the time-point when the next pulse was due. The overall severity of tinea capitis at pretherapy was classified as mild, moderate or severe with the aetiology being: Trichophyton tonsurans, 24 patients; T. violaceum, two patients and Microsporum canis, one patient. In 19 evaluable patients, 12 weeks after starting therapy, the numbers of pulses of itraconazole oral solution required to produce complete cure were, according to the severity of disease, mild tinea capitis (one pulse: four patients; two pulses: five), moderate disease (one pulse: two patients; two pulses: two; three pulses: two), and severe disease (three pulses: three patients). One patient with moderate severity tinea capitis was clinically clear after three pulses of therapy but mycological examination was positive. Seven patients were lost to follow-up and one discontinued therapy because of nausea. Itraconazole oral solution 3 mg/kg per day was generally well tolerated. Three children developed gastrointestinal adverse effects which were considered to be minor or 'nuisance' effects. The data from this preliminary report need to be confirmed in a larger group of patients. It remains to be seen whether itraconazole oral solution will become a practical alternative to the antifungal agents available in a liquid preparation for the treatment of tinea capitis.
Authors:
A K Gupta; R S Solomon; P Adam
Related Documents :
6624768 - Frequency and distribution of senile cardiovascular amyloid. a clinicopathologic correl...
16198068 - 3d optoelectronic analysis of interfractional patient setup variability in frameless ex...
7072588 - Clinical confirmation of ecg criteria for left atrial rhythm.
17434888 - Contemporary catheter ablation of arrhythmias in geriatric patients: patient characteri...
21785288 - Pulmonary nocardiosis: computed tomography features at diagnosis.
10468458 - A retrospective study of the management of oral mucous membrane pemphigoid with dapsone.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The British journal of dermatology     Volume:  139     ISSN:  0007-0963     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-10-19     Completed Date:  1998-10-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  104-6     Citation Subset:  IM    
Affiliation:
Department of Medicine, Sunnybrook Health Science Center, Toronto, Ontario, Canada. agupta@execulink.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Antifungal Agents / therapeutic use*
Child
Child, Preschool
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Itraconazole / therapeutic use*
Male
Tinea Capitis / drug therapy*
Chemical
Reg. No./Substance:
0/Antifungal Agents; 84625-61-6/Itraconazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential response of sebaceous glands to exogenous testosterone.
Next Document:  Sweet's syndrome associated with non-tuberculous mycobacterial infection: a report of five cases.